APO-Pemetrexed pemetrexed 100 mg (as disodium) powder for injection vial

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

pemetrexed disodium hemipentahydrate, Quantity: 120.8 mg (Equivalent: pemetrexed, Qty 100 mg)

Disponible depuis:

Arrotex Pharmaceuticals Pty Ltd

DCI (Dénomination commune internationale):

pemetrexed disodium hemipentahydrate

forme pharmaceutique:

Injection, powder for

Composition:

Excipient Ingredients: mannitol; hydrochloric acid; sodium hydroxide

Mode d'administration:

Intravenous Infusion

Unités en paquet:

1

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell Lung Cancer (NSCLC),Pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology.,Pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Descriptif du produit:

Visual Identification: White to either light yellow or green-yellow powder.; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Statut de autorisation:

Licence status A

Date de l'autorisation:

2014-09-04